Systemic sclerosis & Raynaud's
Hypochromic red cells as a prognostic indicator of survival among patients with systemic sclerosis screened for pulmonary hypertension
Authors' conclusion
This is the first study reporting that HRC > 2% is an independent prognostic predictor of mortality and can possibly be used as a biomarker among SSc patients.
Study context
- Population
- Systemic sclerosis (SSc) patients screened for pulmonary hypertension (PH) with available iron metabolism data (81% female, 60 ± 13 years, 77% limited cutaneous SSc)280 screened
- Participants
- 171 patients
- Exposure
- HRC > 2% vs HRC ≤ 2% at baseline
- Outcome
- Survival (prognostic value of % HRC)
Methodological detailssingle-center, uni- and multivariable analysis, 65 manifest PH, 73 pulmonary fibrosis
- Single-center
- Uni- and multivariable analysis
- 65 manifest PH, 73 pulmonary fibrosis
Main finding
As reported in the abstract
Survival · follow-up 2.4 ± 1.8 (median 2.4) years
- HRC > 2% at baseline significantly associated with worse survival, univariable
- p = 0.018
- HRC > 2% at baseline significantly associated with worse survival, multivariable, independent from PH or pulmonary parenchymal manifestations
- p = 0.031
Observational data: associations, not effects.
Further findings
Survival with combination of HRC > 2% and DLCO ≤ 65% predicted
- Combination significantly associated with survival
- P < 0.0001
Original publication
Hypochromic red cells as a prognostic indicator of survival among patients with systemic sclerosis screened for pulmonary hypertension. Arthritis Res Ther. Published 9 March 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →